Search clinical trials for: 5 mg Linagliptin (Tradjenta)

Total 1261 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Real World Glycemic Effectiveness of Linagliptin

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
International Bio service

Not yet recruiting

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Healthy Volunteer
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Amsterdam UMC, location VUmc

Completed

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS)

Type 2 Diabetes

Netherlands
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
M.H.H. Kramer

Active, not recruiting

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES (RACELINES)

Type2 Diabetes

Netherlands
Boehringer Ingelheim
Eli Lilly and Company

Completed

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Diabetes Mellitus, Type 2

United States, Estonia, Germany, Latvia, Spain, United Kingdom
Dong Wha Pharmaceutical Co. Ltd.

Completed

the Pharmacokinetic Profiles of Linagliptin With DW1029M (PLID)

Healthy

Korea, Republic of
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Rabin Medical Center

Unknown

Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department

DM2
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Medanta, The Medicity, India

Not yet recruiting

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)

Diabetes Mellitus | Kidney Transplant; Complications
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Anesiva, Inc.

Completed

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

Total Knee Arthroplasty (Replacement)

United States
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Linagliptin in Post-renal Transplantation

Transplanted Kidney Complication
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Type II Diabetes
GlaxoSmithKline

Terminated

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Anaemia

United States
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
University at Buffalo
Kaleida Health

Completed

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (1971)

Type 2 Diabetes

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

Asymptomatic Amyloid-positive

United States, Canada, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Denmark, Mexico, Finland, Sweden
Proteimax Biotechnology Israel LTD

Recruiting

Effect of Consumption of Pep19 on Quality of Life

Quality of Life | Obesity | Sleep Quality

United States
George Washington University
Boehringer Ingelheim

Completed

Linagliptin's Effect on CD34+ Stem Cells

Type 2 Diabetes | Impaired Renal Function

United States
GSNOR Therapeutics, Inc.

Unknown

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
Laboratorios Andromaco S.A.

Completed

Bioavailability of Clotiazepam 5 mg With Regards to Reference Product

Bioequivalence

Chile
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
Estetra

Completed

Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers

Menopause | Contraception

Bulgaria
University of Miami

Withdrawn

Effects of DPP4 Inhibition on COVID-19

Coronavirus Infection | Type 2 Diabetes

United States
Bayer
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

Spain, Italy, United States, Sweden, Poland, Argentina, Hungary
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Ferring Pharmaceuticals

Terminated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Israel, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa

3

Subscribe